198821-22-6 | Merimepodib

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$42.00	$29.00
5mg	98%	in stock	$179.00	$126.00
10mg	98%	in stock	$313.00	$219.00
100mg	98%	in stock	$558.00	$391.00
250mg	98%	in stock	$1,086.00	$760.00
1g	98%	in stock	$3,091.00	$2,164.00

Description

• Catalog Number: AB08319
• Chemical Name: Merimepodib
• CAS Number: 198821-22-6
• Molecular Formula: C23H24N4O6
• Molecular Weight: 452.4599
• MDL Number: MFCD09837807
• SMILES: COc1cc(ccc1c1cnco1)NC(=O)Nc1cccc(c1)CNC(=O)O[C@@H]1COCC1

Computed Properties

• Complexity: 652
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 8
• XLogP3: 2.1

Literature

• Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.

  Hepatology (Baltimore, Md.) 20091201

• Ribavirin analogs.

  Clinics in liver disease 20090801

• Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.

  Journal of hepatology 20071001

• Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400.

  Journal of pharmaceutical and biomedical analysis 20070411

• Low molecular weight indole fragments as IMPDH inhibitors.

  Bioorganic & medicinal chemistry letters 20060501

• A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.

  Antiviral therapy 20050101

• Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes.

  Biochemical pharmacology 20040215

• 3-cyanoindole-based inhibitors of inosine monophosphate dehydrogenase: synthesis and initial structure-activity relationships.

  Bioorganic & medicinal chemistry letters 20031020

• Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl moiety.

  Bioorganic & medicinal chemistry letters 20030616

• The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA.

  Virology 20030605

• Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity.

  Journal of medicinal chemistry 20020523

• VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent.

  Journal of pharmaceutical sciences 20010501

• Current and future therapies of hepatitis C.

  Clinics in liver disease 20010501

• New dermatological agents for the treatment of psoriasis.

  Journal of medicinal chemistry 20010201

• The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves graft versus host disease in mice.

  Drugs under experimental and clinical research 20010101

• Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon.

  Antimicrobial agents and chemotherapy 20000401

• Novel approaches to the treatment of hepatitis C virus infection.

  Antiviral chemistry & chemotherapy 20000301